UNSPSC 51361501: Chloral hydrate

This classification denotes an adjuvant analgesic with the molecular formula C2H3Cl3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 418M5916WG, chemically known as 2,2,2-trichloroethane-1,1-diol but generally known as chloral hydrate, which bears US NIH Compound Identifier 2707. European Medicines Agency schedules Chloral hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13324MIG. World Health Organization schedules chloral hydrate in its Anatomical Therapeutic Chemical (ATC) Classification.

As of Q4 2014, CHLORAL HYDRATE remains the US FDA Preferred Term for this commodity. Chloral hydrate bears US NLM identifiers UMLS ID C0008161 and NCI Concept Code C28922. SMILES: C(C(Cl)(Cl)Cl)(O)O.

UNSPSC 51361501 Chloral hydrate is a Commodity code that captures pharmaceutical procurement by state and local health agencies, though recent opportunities under this designation show limited direct alignment with the code's specific substance focus. State and local governments are purchasing pharmaceutical products through this code path primarily via health departments and cooperative purchasing alliances, which acquire generic pharmaceuticals, over-the-counter products, naloxone, and related medical supplies for public health initiatives and employee health plans. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing entities like MMCAP; these jurisdictions typically solicit through RFPs and IFBs with multi-vendor awards and extended contract terms of two years or longer.

Activity appears concentrated in the South and Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to serve participating state and local facilities across multiple states including Oregon, with a March 26, 2026, response deadline and July 1, 2026, contract effective date. Vendors must comply with cGMP certification, Drug Supply Chain Security Act requirements, and FDA standards, and maintain substantial insurance coverage including commercial general liability of $5 million per occurrence.